HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on ProPhase Labs (NASDAQ:PRPH) and maintained a $14 price target.
June 02, 2023 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProPhase Labs (NASDAQ:PRPH) receives a reiterated Buy rating and a maintained $14 price target from HC Wainwright & Co. analyst Yi Chen.
The reiterated Buy rating and maintained $14 price target by HC Wainwright & Co. analyst Yi Chen indicates a positive outlook for ProPhase Labs. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100